VAG + FLT3 inhibitor vs standard chemo for FLT3-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares a new two-drug combination (VAG plus a FLT3 inhibitor) against standard chemotherapy plus a FLT3 inhibitor for adults with newly diagnosed FLT3-mutated AML. The goal is to see which approach works better in stopping the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of a type of AML that involves a FLT3 mutation (either ITD or TKD).
- You are between 14 and 74 years old and are healthy enough to receive strong chemotherapy.
- Your doctors are recommending intensive chemotherapy (a strong treatment to kill leukemia cells).
- You have acceptable liver, kidney, and heart function (checked by simple tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
This trial tests a new combination of three drugs (gilteritinib, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) that no longer responds to azacitidine and venetoclax. The goal is to see if this triple therapy can help achieve remission and improve outcomes.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This trial tests a targeted therapy for people with a specific genetic change in their AML cells called FLT3-ITD. It aims to see if adding this targeted drug to standard chemotherapy improves outcomes for patients who are otherwise healthy enough to receive intensive treatment.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.